Guiding Principles of Good AI Practice in Drug Development: What Every Regulatory Professional Needs to Know
- Jul 9
- 12 min read
In January 2026, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) jointly published one of the most significant regulatory science documents in recent memory: Guiding Principles of Good AI Practice in Drug Development. For the first time, the world's two most influential regulatory authorities have aligned on a shared framework governing how artificial intelligence must be developed, validated, documented, and managed across the entire pharmaceutical development lifecycle.
This is not a distant regulatory horizon. The FDA's Centre for Drug Evaluation and Research (CDER) has already confirmed a significant and accelerating growth in AI incorporation across all categories of drug application submissions. Regulators are reviewing AI-generated data, AI-analysed clinical datasets, and AI-assisted manufacturing outputs today. For pharmaceutical companies, biotech developers, medical device manufacturers, and the regulatory professionals who support them, the question is no longer whether to engage with these principles. It is how thoroughly and how urgently.
Launch Your Regulatory Affairs Career Including AI and Digital Health Regulation At Entry to Regulatory, we provide intensive, practical training courses for anyone looking to break into Regulatory Affairs — even with zero prior experience. Our programme covers EU, US, and UK regulations over 50+ CPD hours, pairs you with real-world work assignments, and gives you dedicated CV support, mock interviews, and job placement mentoring. Graduates are landing roles within weeks to months of completing the course. it. Speak to us and see how we can help you.
Why a Joint FDA-EMA AI Framework Matters Right Now
To appreciate the significance of this document, consider the scale of AI's current penetration into drug development:
- Drug discovery: Generative AI models are designing novel molecular structures; predictive models are screening billions of compounds for toxicity, binding affinity, and pharmacokinetic behaviour at speeds no human team could match
- Clinical development: AI is being used for patient selection and stratification, adaptive trial design, biomarker identification, and analysis of complex multi-modal clinical datasets
- Manufacturing and CMC: Real-time process monitoring, predictive quality control, and continuous manufacturing optimisation are all increasingly AI-driven
- Pharmacovigilance: AI is detecting safety signals from vast adverse event databases, monitoring real-world evidence, and tracking population-level drug safety at a scale impossible through manual review
The CDER AI Council — established specifically to coordinate AI-related regulatory activity — has observed AI appearing across every phase of drug development submissions. The complex and dynamic processes involved in developing, deploying, and maintaining AI require careful management throughout the drug product lifecycle to ensure outputs are accurate, reliable, and — critically — defensible to a regulator.
The January 2026 joint FDA-EMA document establishes the framework within which all of that activity must now operate. Here is what each of the 10 principles means, why it matters, and what it requires in practice.
The 10 Guiding Principles: A Complete Breakdown
Principle 1 — Human-Centric by Design
"The development and use of AI technologies align with ethical and human-centric values."
This is the ethical foundation of the entire framework. Every AI application in drug development must ultimately serve patients — their safety, their access to effective medicines, and the integrity of the scientific record on which treatment decisions are based.
In regulatory terms, human-centric design means AI must support and augment qualified human judgement — never circumvent or replace it. A regulatory reviewer, clinical scientist, or manufacturing quality lead must be able to understand, evaluate, and take responsibility for any AI output that informs a consequential decision.
It also means equity by design: AI systems trained on datasets that underrepresent patients by age, sex, ethnicity, or geography may produce outputs that are accurate for the training population but unreliable — or dangerous — for others. This is not an abstract concern. Clinical trial populations have historically been unrepresentative of the patients who ultimately receive approved medicines, and AI trained on those datasets inherits those gaps.
Principle 2 — Risk-Based Approach
"AI technologies follow a risk-based approach with proportionate validation, risk mitigation, and oversight based on the context of use and determined model risk."
Not all AI carries the same regulatory risk. An AI model used to screen early-stage compounds in discovery carries fundamentally different risk than one used to analyse the primary endpoint dataset of a pivotal Phase III trial. The validation, documentation, and oversight applied must be proportionate to the actual risk of the specific application.
This principle echoes the familiar ICH Q9 quality risk management philosophy — applying rigour where it is genuinely needed, rather than imposing a single standard across all applications regardless of consequence. Companies need to build internal AI risk classification frameworks that tier their AI applications and define the corresponding governance requirements for each tier.
Principle 3 — Adherence to Standards
"AI technologies adhere to relevant legal, ethical, technical, scientific, cybersecurity, and regulatory standards, including Good Practices (GxP)."
AI is not exempt from existing regulatory requirements. Systems operating within GxP environments — GLP for nonclinical research, GCP for clinical trials, GMP for manufacturing — must comply with those requirements fully. Using a commercially available AI platform does not automatically confer GxP compliance.
This principle has particular implications for the growing use of third-party AI tools in regulated pharmaceutical environments. Every AI tool used to generate data that enters a regulatory submission, or to support a GxP-compliant manufacturing or quality process, must be evaluated against the applicable GxP standards — including computerised system validation (CSV), data integrity requirements, and cybersecurity obligations.
Principle 4 — Clear Context of Use
"AI technologies have a well-defined context of use — role and scope for why it is being used."
Every AI system deployed in drug development must have a precisely documented context of use — what it does, what data it processes, what outputs it produces, and in what decision-making context those outputs are applied. Vague descriptions like "AI was used to analyse the dataset" are not acceptable in regulatory submissions.
The context of use must specify the model type, training data provenance, intended outputs, validation approach, and human oversight mechanism. For regulatory affairs professionals writing submissions, this creates a new layer of technical documentation that requires both scientific and AI literacy.
Principle 5 — Multidisciplinary Expertise
"Multidisciplinary expertise covering both the AI technology and its context of use are integrated throughout the technology's life cycle."
This is one of the most practically significant principles for the pharmaceutical workforce. Developing and deploying AI in drug development requires genuine expertise in both AI technology and the scientific or clinical domain. A data scientist without pharmacological knowledge is not sufficient. A clinical scientist who cannot evaluate model performance is not sufficient. Both are necessary and must work together throughout the entire AI system lifecycle.
For regulatory professionals, this creates an explicit expectation of cross-functional fluency — the ability to work productively with both AI development teams and domain scientists to ensure that AI applications meet regulatory requirements from design through to post-market monitoring.
Principle 6 — Data Governance and Documentation
"Data source provenance, processing steps, and analytical decisions are documented in a detailed, traceable, and verifiable manner, in line with GxP requirements."
Data quality is the foundation of AI reliability. An AI model is only as good as the data it was trained on — and a regulatory reviewer can only evaluate an AI system as well as its data documentation allows them to. The principle requires full traceability of:
- Where training data came from — including any public datasets, real-world data sources, or third-party databases
- How data was processed — cleaning, normalisation, imputation, feature engineering decisions
- What analytical choices were made — model architecture, hyperparameters, feature selection
- How patient data privacy is protected — particularly for AI systems trained on sensitive clinical datasets
The familiar GxP ALCOA+ data integrity framework (Attributable, Legible, Contemporaneous, Original, Accurate — plus Complete, Consistent, Enduring, Available) applies to AI data governance in full. This represents a significant documentation investment for companies that have not previously formalised their AI data management processes.
Principle 7 — Model Design and Development Practices
"AI development follows best practices in model and system design, considering interpretability, explainability, and predictive performance, promoting transparency, reliability, generalisability, and robustness."
This principle directly addresses the "black box" problem — arguably the most contentious regulatory challenge posed by modern AI. Many high-performing AI models, particularly deep neural networks, generate predictions through processes that are not transparent or interpretable to human reviewers. In a regulatory context, where every significant scientific claim must be explicable and defensible, this presents a fundamental problem.
The principle establishes that interpretability and explainability are not optional enhancements but design requirements for regulatory-facing AI. When an AI model analyses clinical trial data, detects a safety signal, or supports a manufacturing release decision, regulators must be able to understand — meaningfully — why the model produced the output it did.
The principle also emphasises generalisability and robustness — a model that performs well on its training data but fails on new data (overfitting) is not fit for regulatory purposes. Validation must demonstrate performance on independent datasets representative of real-world deployment.
Principle 8 — Risk-Based Performance Assessment
"Performance assessments evaluate the complete system including human-AI interactions, using appropriate metrics for the intended context of use, supported by validation of predictive performance."
AI performance assessment goes beyond whether a function executes correctly. It must evaluate whether predictions are accurate, unbiased, and reliable in the specific context of intended use. Crucially, this principle requires assessment of the complete system — including how human operators interact with and respond to AI outputs.
An AI model may perform well in isolation but produce poor outcomes in practice if human operators systematically override, misinterpret, or over-rely on its recommendations. This human-in-the-loop evaluation dimension is a genuinely new requirement for pharmaceutical validation frameworks.
Principle 9 — Life Cycle Management
"Risk-based quality management systems are implemented throughout the AI technologies' life cycles, including scheduled monitoring and periodic re-evaluation to ensure adequate performance — for example, to address data drift."
This principle addresses one of the most distinctive characteristics of AI systems: they can degrade over time. As the real-world data encountered in deployment diverges from the distribution of training data — a phenomenon known as data drift — model performance declines. A pharmacovigilance AI trained on historical adverse event data may become less sensitive as clinical practice, patient populations, or reporting patterns evolve.
The principle requires ongoing monitoring and periodic re-evaluation of all deployed AI systems — not just at launch but throughout their operational life. Companies must develop formal AI change control procedures covering retraining, re-validation, and the conditions under which a model must be retired and replaced. This is a direct extension of GxP lifecycle management principles into the AI domain.
Principle 10 — Clear, Essential Information
"Plain language is used to present clear, accessible, and contextually relevant information to the intended audience regarding the AI technology's context of use, performance, limitations, underlying data, and interpretability."
The final principle is about communication. Every AI system used in drug development must be accompanied by clear, accurate, plain-language documentation — in regulatory submissions, internal governance records, and any patient-facing materials.
Regulatory reviewers evaluating submissions that contain AI-generated or AI-analysed data must be able to understand what the AI did, how it was validated, what its limitations are, and why its outputs should be trusted. The ability to translate complex AI methodology into regulatory-standard language is a premium skill — and one that sits squarely in the regulatory affairs professional's domain.
The Business Implications: What Companies Must Do Now
The FDA-EMA principles are not a distant compliance challenge — they apply to AI systems that are already in use across the industry. Here is the practical action plan for pharmaceutical and biotech organisations:
✅ Conduct an AI inventory audit
Map every AI system currently in use across the drug development programme. Identify which systems generate data that enters regulatory submissions or informs GxP-relevant decisions. These are your highest-priority systems for principles compliance assessment.
✅ Implement an AI risk classification framework
Not all AI requires the same level of governance. Build a tiered classification system — aligned with Principle 2 — that defines validation, documentation, and oversight requirements proportionate to the regulatory risk of each application.
✅ Establish data governance processes for AI
Implement full provenance tracking for all data used to train, validate, and deploy regulatory-facing AI systems. This means more than typical data management — it means ALCOA+-compliant documentation of every processing step, analytical decision, and governance measure applied to AI training datasets.
✅ Build interpretability into model selection
When choosing AI models for regulatory-facing applications, weight interpretability and explainability alongside predictive performance. The most accurate model is not necessarily the most appropriate model if its reasoning cannot be explained to a regulatory reviewer.
✅ Develop AI lifecycle management procedures
Create formal procedures for ongoing AI monitoring, performance re-evaluation, retraining decisions, and model retirement. Data drift monitoring should be built into the operational plan for every deployed AI system in a regulated environment.
✅ Train cross-functional teams
Invest in AI literacy across clinical, regulatory, manufacturing, and pharmacovigilance functions. Simultaneously, invest in domain and regulatory literacy for AI development and data science teams. Principle 5 makes this cross-pollination a regulatory expectation, not merely best practice.
The Career Opportunity: Why AI Regulatory Expertise Is One of the Most Valuable Skills in 2026
The FDA-EMA principles are creating a new category of professional demand — one that sits at the intersection of regulatory science, data science, and pharmaceutical development strategy. It is a combination that is genuinely scarce and commanding a significant market premium.
The Numbers Tell the Story
- The regulatory affairs job market is projected to add 94,400 new positions by 2032, driven by increasing regulatory complexity across digital health, AI, biologics, and advanced therapies
- Regulatory Affairs Specialists are earning around $105,000 on average in the US, with specialist roles in pharmaceutical and biotechnology sectors reaching $130,000–$140,000
- Professionals who combine regulatory affairs expertise with AI governance and digital health knowledge are among the most sought-after profiles in pharmaceutical hiring globally
- Life sciences recruitment specialists identify regulatory strategists with cross-functional AI and digital capabilities as the defining talent gap in European and US pharmaceutical hiring in 2026
The skills now most urgently in demand include:
- Understanding how AI systems must be documented and validated for regulatory submissions
- Writing regulatory-standard descriptions of AI methodology in plain, defensible language
- Evaluating AI-generated data packages for GxP compliance
- Managing the interface between AI development teams and regulatory strategy
- Understanding lifecycle management obligations for deployed AI in GxP environments
These are not data science skills. They are regulatory science skills — applied to a new class of technology. And they are skills that regulatory affairs training programmes are only beginning to address.
Choosing the Right Training: What the Market Is Looking For
The emergence of AI governance as a regulatory affairs competency has sharpened employers' focus on what they expect from candidates. Here is an honest comparison of the available training pathways:
The consistent message from pharmaceutical employers in 2026 is unchanged but intensified by the AI dimension: they want candidates who can engage with real regulatory documents and real compliance challenges — not candidates who can answer multiple-choice questions about regulatory theory.
As AI governance becomes embedded in regulatory affairs practice, the premium on genuine, documented, hands-on regulatory experience — the kind that demonstrates you can actually operate in a regulated pharmaceutical environment — will only increase.
Key Takeaways
The FDA-EMA Guiding Principles of Good AI Practice in Drug Development represent a generational shift in how regulators approach the fastest-growing category of pharmaceutical technology. Whether you are a pharmaceutical company using AI in development, a regulatory professional advising on submissions, or someone building a career in regulatory science, the direction of travel is clear:
- ✅ AI in drug development is already regulated — the principles establish the framework within which all AI applications must now operate
- ✅ Explainability and interpretability are mandatory design requirements — not optional features of high-performing AI systems
- ✅ GxP applies fully to AI — existing data integrity, computerised systems validation, and lifecycle management obligations extend to every AI system in a regulated environment
- ✅ Lifecycle management is an ongoing obligation — data drift monitoring and periodic model re-evaluation are not optional
- ✅ Multidisciplinary expertise is explicitly required — regulatory professionals who understand both AI technology and regulatory science are the professionals this market needs
- ✅ The career opportunity is real and significant — AI regulatory expertise is among the most valuable and highest-compensated specialisms in pharmaceutical regulatory affairs in 2026
Ready to Build Your Career in Regulatory Affairs — Including the AI Era?
The FDA-EMA guiding principles are reshaping what it means to work in regulatory affairs. The professionals who will thrive in this landscape are those who combine solid regulatory science foundations with the ability to navigate the evolving world of AI, digital health, and data governance. That combination is what employers are looking for — and it is what the best regulatory affairs training is designed to deliver.
At Entry to Regulatory, we provide training courses for anyone trying to build a career in Regulatory Affairs — no previous experience required. Our programme gives you the regulatory knowledge, hands-on document experience, and career support that make the difference between applying for roles and landing them.
Here is what you get when you train with us:
- 📋 50+ CPD hours covering EU, US, and UK regulatory frameworks — the foundation every employer in pharmaceutical regulatory affairs expects
- 🔬 Real-world work assignments on actual regulatory documents — the hands-on experience that sets your CV apart in a competitive market
- 🧑💼 Dedicated career support — CV reviews, mock interviews, and job placement mentoring from people inside the regulatory affairs hiring world
- 🌐 A professional community of peers, graduates, and industry connections that supports your career long after the programme ends
- 🏆 Proven graduate outcomes — UK roles paying upwards of £50,000, US roles offering $100,000+, with graduates landing positions within weeks to months of completing the course
Whether you are entering the profession for the first time, transitioning from a science or clinical background, or building on existing experience in a new direction — we can help you develop the skills and confidence to compete in one of the most dynamic regulatory landscapes in history.
About the Author: Rabiea is an Honorary Associate Professor at UCL, former MHRA Health Authority reviewer, and CEO of Entry to Regulatory and Advanced Regulatory Consulting. After transitioning from retail pharmacy to regulatory affairs, she has dedicated her career to helping others make the same successful career change. Connect with her on LinkedIn for the latest regulatory affairs insights and career advice.
Comments